



**MaineCare Services**  
 An Office of the  
 Department of Health and Human Services

John E. Baldacci, Governor

Brenda M. Harvey, Commissioner

Department of Health and Human Services  
 MaineCare Services  
 442 Civic Center Drive  
 # 11 State House Station  
 Augusta, Maine 04333-0011  
 Tel: 1-866-796-2463; Fax: (207) 287-8601  
 TTY: 1-800-423-4331

TO: Maine Drug Utilization Review Board  
 FROM: Sally Griffith-Onnen  
 DATE: March 10 2010  
 RE: Maine DUR Board meeting minutes from March 9, 2010

<b>ATTENDANCE</b>	<b>PRESENT</b>	<b>ABSENT</b>	<b>EXCUSED</b>
<i>Lisa Wendler, Pharm. D., Clinical Pharmacy Specialist, Maine Medical CTR, Chair</i>	<i>x</i>		
<i>Jeffrey Barkin, MD Psychiatrist</i>	<i>x</i>		
<i>William Alto, M.D. Family Practice, Dartmouth Family Practice Faculty</i>	<i>x</i>		
<i>Laureen Biczak DO, Infectious Disease, GHS</i>			<i>x</i>
<i>Mark Braun, M.D., FACP, Internist/Geriatrician</i>			<i>x</i>
<i>Timothy Clifford, M.D., Family Practice, GHS</i>	<i>x</i>		
<i>Amy Enos, Pharm. D. Waltz LTC Pharmacy</i>	<i>x</i>		
<i>Jack Forbush, D.O., Family Medicine</i>			
<i>Steven Gressit, M.D. Psychiatrist, DHHS Mental Health Medical Director</i>	<i>x</i>		
<i>Steven Meister MD, Pediatrician, Maine CDC, Division Family Health Medical Director</i>			<i>x</i>
<i>Mike Ouellette, R.Ph. GHS</i>	<i>x</i>		
<i>Laurie Roscoe, R.Ph. Martin's Point</i>	<i>x</i>		
<i>Robert Weiss MD, Cardiologist</i>			<i>x</i>
<b>Non - Voting</b>			
<i>Jennifer Palow, Pharmacy Manager, OMS</i>			<i>x</i>
<i>Brenda McCormick, Director OMS</i>	<i>x</i>		
<i>Rod Prior MD, Medical Director OMS</i>			<i>x</i>

**Call to order**

The meeting was called to order at 6:00pm.

*Caring..Responsive..Well-Managed..We are DHHS.*

## Welcome of the members of the Psychiatric Work Group

The Chair formally welcomed the members of the Maine Psychiatric work group to the meeting. Members representing the Psychiatric Work Group Committee were:

- Elsie Freeman, MD, MPH, Medical Director Behavioural Health at DHHS
- Ben Crocker, MD, Psychiatrist at the Crisis and Counseling Center
- Julie Pease, MD, Psychiatrist
- Lindsey Tweed, MD, Psychiatrist at Maine Medical Center's Department of Psychiatry
- Patrick Maidman, MD, Psychiatrist at Counseling Services Inc

### DUR Minutes from February

A motion was made and seconded to accept the minutes as written from the February meeting. The motion was passed.

### Public Comments

Jennifer Reck from Prescription Policy Changes, a non-profit organization based in Hallowell, introduced herself to the board.

### Atypical Antipsychotic Project Presentation

Dr Elsie Freeman and Dr Lindsey Tweed gave a presentation on the multi-state atypical antipsychotic project to the board. Afterwards the committee discussed the data, particularly in terms of the foster children population.

### New Business

#### Atypical Antipsychotic Age Edits

Dr Barkin presented information on Antipsychotic FDA Indications by Age to the Board. He stated that minimum age edits would be appropriate for these drugs. Dr Clifford spoke about creating edits requiring prior authorizations for children under five years. Dr Barkin said that he would come up with an easy to use PA process with the aim of gathering information. The PA would have an automatic approval but would require the prescriber to provide information regarding the context of the treatment and the basis of diagnosis. He will present his draft to the next Psychiatric Work Group meeting.

Dr Clifford spoke of the need to have a program focusing on adherence for antipsychotics. Dr Freeman suggested that children prescribed antipsychotics would be a good first group to look at and that in the case of foster children information regarding non picked up prescriptions should be sent to both the prescriber and the case manager. Dr Clifford will give the current non adherence rates to the DUR and Psych Work Group next month. Dr Clifford presented a draft template letter for prescribers to the board and the Psychiatric Work Group for comment, with a goal of implementation in May.

A vote on the edit was deferred until the April Meeting

#### Safety Issues for mental health drugs

**Atypical metabolic monitoring:** Dr Barkin said that glucose and lipid testing should take place to establish a baseline within six months of the start of an atypical antipsychotic. Dr Clifford said that he would look at the most recent year and what percent of patients had met this standard. An edit similar to a drug-drug interaction edit could be set up so that prescribers would be informed if their patient had not had a test done within the six month timeframe as part of a quality improvement project.

*Caring..Responsive..Well-Managed..We are DHHS.*

**Childbearing women on Depakote:** Children born to women on Depakote have a risk of neural tube defects and low IQ. Similarly to the atypical metabolic monitoring edit, a fax could be generated for prescribers who give scripts for Depakote to women of childbearing age. The wording of the fax will be discussed in the Psychiatric Work Group. Dr Clifford will get the data on females in all age groups prescribed Depakote and whether they have a seizure flag and give the data to the Psychiatric Work Group.

### **Adjournment**

The meeting concluded at 8:25. The next meeting will be held April 13 2010.

*Caring..Responsive..Well-Managed..We are DHHS.*